|
|
|
| home > ict > spring 2020 > pushing ‘go’ again on clinical trials in a post-covid-19 world |
|
|
 PUBLICATIONS |
Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time.
Sign up now!
Already registered? Please sign in.
Alternatively, please use our pay-per-view service. |
|
|
 |
News and Press Releases |
 |
GSK Announces Positive Pivotal Phase III Data for its Respiratory Syncytial Virus (RSV) Vaccine Candidate for Older Adults
GSK plc (LSE/NYSE: GSK) today announced positive headline results
from a pre-specified efficacy interim analysis of the AReSVi 006 phase
III trial. The interim analysis was reviewed by an Independent Data
Monitoring Committee, and the primary endpoint was exceeded with no
unexpected safety concerns observed. AReSVi 006 is a phase III trial
investigating GSK’s respiratory syncytial virus (RSV) vaccine candidate
for adults aged 60 years and above.
More info >> |
|
|
